Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 4 | FDP00721 | IM |
The patient received second dose six days after first dose, third dose ten days after the first dose and fourth dose seventeen days after the first dose; Case reference number US-BN-2026-000411 is a spontaneous case initially received from a nurse via Bavarian Nordic (reference number: CASE-002459) on 03-Mar-2026 and concerns a *67-years-old* female patient. The patient's medical history and concomitant medication details were not provided. On 25-Feb-2026, the patient received the first dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: *FDP00721, Expiry date: 31-Jan-2028*), *at a dose of 1ml via intramuscular route* unknown site of administration for post exposure and *cat bite*. *On 03-Mar-2026, six days after the first dose, the patient received second dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: FDP00722, Expiry date: 31-Dec-2027), *at a dose of 1ml via intramuscular route* unknown site of administration (explicitly coded as inappropriate schedule of vaccine administered').* *On 07-Mar-2026, ten days after the first dose, the patient received third dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: FDP00553, Expiry date: 31-Dec-2027) *at a dose of 1ml via intramuscular route* unknown site of administration (explicitly coded as inappropriate schedule of vaccine administered').* *On 14-Mar-2026, seventeen days after the first dose, the patient received fourth dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: FDP00721, Expiry date: 17-Jan-2027) *at a dose of 1ml via intramuscular route* unknown site of administration (explicitly coded as inappropriate schedule of vaccine administered').* At the time of *follow-up* report, the patient *did not* experienced any adverse events due to RabAvert. All follow up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow-up information received from nurse on 30-Mar-2026: New information included RabAvert dosing details, patient demographics and confirmation that no adverse event experienced due to RabAvert.; Reporter's Comments: A 67-year-old female patient received the second, third and the fourth dose of RabAvert vaccine for post exposure and cat bite, respectively on the days 6, 10 and 17 after the first dose, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse events due to RabAvert. Inappropriate schedule of vaccine administered is expected as per company conventions. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. The case is non-serious.; Sender's Comments: A 67-year-old female patient received the second, third and the fourth dose of RabAvert vaccine for post exposure and cat bite, respectively on the days 6, 10 and 17 after the first dose, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse events due to RabAvert. Inappropriate schedule of vaccine administered is expected as per company conventions. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. The case is non-serious.
Comments: None